Clinical Trial Update: HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's-Tyrosine Kinase Inhibitor (BTK-I) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating HEPLISAV-B hepatitis B vaccine in patients with chronic lymphocytic leukemia, including those treated with BTK inhibitors; study comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• HEPLISAV-B (hepatitis B vaccine, adjuvanted)

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Hepatitis, Safety and Tolerability | Phase 2 | Status: COMPLETED | Results posted: 2021-12-15